Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 4,802 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sensitivity Clear all
Completed Phase 3 Interventional Results available

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

NCT03131648
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
44
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 23, 2026, 12:02 AM EDT
Completed Early Phase 1 Interventional

Brown Fat Activation Study

NCT02919176
View directory record Official record
Conditions
Obese, Metabolic Syndrome
Interventions
Mirabegron, Pioglitazone, Mirabegron and Pioglitazone
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 23, 2026, 12:02 AM EDT
Active, not recruiting Phase 3 Interventional

Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children

NCT03013517
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250µg
Drug
Lead sponsor
DBV Technologies
Industry
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
17
States / cities
Little Rock, Arkansas • San Diego, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 23, 2026, 12:02 AM EDT
Completed Phase 4 Interventional

The Effect of Cetirizine on Bronchoconstriction

NCT03340740
View directory record Official record
Conditions
Allergic Rhinitis, Asthma
Interventions
Cetirizine Hydrochloride 1 MG/ML, Placebo - Concentrate
Drug
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
6 Years to 20 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 23, 2026, 12:02 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

NCT04250350
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • North Little Rock, Arkansas • Canoga Park, California + 38 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2023 · Synced Oct 23, 2026, 12:02 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)

NCT04612725
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Benralizumab, Placebo and Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Mission Viejo, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 23, 2026, 12:02 AM EDT
Withdrawn Phase 2 Interventional

Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 Diabetes

NCT05035368
View directory record Official record
Conditions
Type I Diabetes
Interventions
Ladarixin, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
21 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 23, 2026, 12:02 AM EDT
Completed Phase 1 Interventional

Antibody Treatment for Advanced Celiac Disease

NCT01893775
View directory record Official record
Conditions
Celiac Disease, Celiac Sprue, Gluten Enteropathy, Gluten-Sensitive Enteropathy
Interventions
Hu-Mik- Beta-1
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 23, 2026, 12:02 AM EDT
Completed Phase 3 Interventional Results available

A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

NCT05372419
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
36
States / cities
Birmingham, Alabama • Fountain Valley, California • Fremont, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 23, 2026, 12:02 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis

NCT05870865
View directory record Official record
Conditions
Dermatitis, Atopic, Pruritus
Interventions
ASN008, ASN008 Matching Vehicle
Drug · Other
Lead sponsor
Formation Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
27
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 23, 2026, 12:02 AM EDT
Completed Phase 1 Interventional Results available

Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma

NCT02260492
View directory record Official record
Conditions
Asthma
Interventions
OT329 (combination of fluticasone propionate and salmeterol xinafoate), Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate), Placebo
Drug
Lead sponsor
Oriel Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
47
States / cities
Goodyear, Arizona • Tempe, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Oct 23, 2026, 12:02 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis

NCT03257644
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib phosphate cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
2 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
23
States / cities
Hoover, Alabama • Gilbert, Arizona • Little Rock, Arkansas + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 23, 2026, 12:02 AM EDT
Completed No phase listed Observational

Observational Assessment of Baseline Asthma Control in African-American Children

NCT01891630
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2015 · Synced Oct 23, 2026, 12:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Functionally Validated Structural Endpoints for Early AMD

NCT04112667
View directory record Official record
Conditions
Age-related Macular Degeneration, Aging
Interventions
Normal Macular Health, Early Macular Degeneration, Young Normals
Other
Lead sponsor
Cynthia Owsley
Other
Eligibility
20 Years and older
Enrollment
556 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 23, 2026, 12:02 AM EDT
Completed Not applicable Interventional

Social Support and Education in Asthma Follow-up (SSEA)

NCT00149500
View directory record Official record
Conditions
Asthma
Interventions
Coaching
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
2 Years to 10 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 23, 2026, 12:02 AM EDT
Completed Early Phase 1 Interventional

A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease

NCT01274507
View directory record Official record
Conditions
Asthma, Pulmonary Disease, Chronic Obstructive
Interventions
Medical tests
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
9
States / cities
Birmingham, Alabama • New Haven, Connecticut • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Oct 23, 2026, 12:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Clinical Study to Investigate the Antihypersensitivity Efficacy of a Novel Dentifrice

NCT07215767
View directory record Official record
Conditions
Dentin Hypersensitivity
Interventions
Stannous fluoride and Potassium nitrate Dentifrice, Stannous fluoride Dentifrice, Potassium nitrate Dentifrice, Vehicle Dentifrice
Drug
Lead sponsor
HALEON
Industry
Eligibility
12 Years to 65 Years
Enrollment
688 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Melbourne, Florida • Fort Wayne, Indiana • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 12:02 AM EDT
Completed No phase listed Observational

Outdoor Allergen Exposure, Sensitivity, and Acute Asthma

NCT00043992
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
15 Years to 50 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 4, 2006 · Synced Oct 23, 2026, 12:02 AM EDT
Active, not recruiting Phase 2 Interventional

Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

NCT03010436
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Drug
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 23, 2026, 12:02 AM EDT
Completed Not applicable Interventional Results available

Predicting Peanut Anaphylaxis and Reducing Epinephrine

NCT05696236
View directory record Official record
Conditions
Anaphylaxis Food
Interventions
Transepidermal water loss (TEWL) monitor and stopping rules, Monitor (TEWL) without stopping rules
Device
Lead sponsor
University of Michigan
Other
Eligibility
6 Months to 5 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 23, 2026, 12:02 AM EDT
Not listed No phase listed Observational

Effect of Montelukast on Basophils, In-vitro

NCT00710450
View directory record Official record
Conditions
Allergic Asthma, Allergic Rhinitis
Interventions
Not listed
Lead sponsor
Creighton University
Other
Eligibility
12 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 23, 2011 · Synced Oct 23, 2026, 12:02 AM EDT
Completed No phase listed Observational

Somatization, Anxiety, and Disordered Sleep in Pediatric Eosinophilic Esophagitis

NCT04309786
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
8 Years to 18 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 23, 2026, 12:02 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

NCT04126070
View directory record Official record
Conditions
Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma
Interventions
Androgen Deprivation Therapy, Nivolumab, Docetaxel
Drug
Lead sponsor
Xiao X. Wei, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
La Jolla, California • Tampa, Florida • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 12:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Expressive Writing in Improving the Wellbeing or Comforting Capacity of Caregivers of Patients With Cancer

NCT02339870
View directory record Official record
Conditions
Caregiver
Interventions
Psychosocial Support for Caregiver, Questionnaire Administration, Sham Intervention
Other
Lead sponsor
University of Washington
Other
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 23, 2026, 12:02 AM EDT